⌕
Relay Therapeutics · RLAY · Nasdaq
Tenet 43 · Weak
Compare
$18.09+0.06%At closeTenet 43 · Weak
$18.09+0.01 (+0.06%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Relay Therapeutics (RLAY) Stock

Relay Therapeutics (RLAY) closed at $18.09 on Nov 13, 2026; its Tenet Score is 43 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

34 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$18.09
Nov 13, 2026
Market cap
$4.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
6.04 – 21.27
low → high · as of close, Nov 13, 2026
Tenet Score
43/100
Weak · 313 Healthcare peers

Industry: Drugs

Relay Therapeutics Inc scores 43/100. Weak. Strongest on financial health, growth is the soft spot versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
47
Quality
38
Health
85
Growth
1

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityDHealthBGrowthFMomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
4.9×
price to book value
P/S
386.2×
price to fiscal 2025 sales
ROE
−41%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
14.62
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indicat…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 94 US ETFs · top wrappers by weightSee all ETFs holding RLAY →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Relay Therapeutics in?

Relay Therapeutics is in the Healthcare sector and the Drugs industry.

What is Relay Therapeutics' Tenet Score?

Relay Therapeutics' Tenet Score is 43 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.